FDA Begins Product Approval Initiative: In an Ideal World, All New Medical Products Proven to Be Safe and Effective Would Be Approved the First Time They Were Considered by the Food and Drug Administration. A Company Would Submit an Application with All the Required Information, and the Agency Would Perform a Timely Review and Then Approve the Product for Marketing

By Lewis, Carol | FDA Consumer, May-June 2003 | Go to article overview

FDA Begins Product Approval Initiative: In an Ideal World, All New Medical Products Proven to Be Safe and Effective Would Be Approved the First Time They Were Considered by the Food and Drug Administration. A Company Would Submit an Application with All the Required Information, and the Agency Would Perform a Timely Review and Then Approve the Product for Marketing


Lewis, Carol, FDA Consumer


In reality, though, most medical products take more than one agency review cycle to be approved. Poorly designed studies and missing scientific information are just two of the possible reasons that applications often undergo multiple reviews that ultimately lengthen approval times.

If problems and deficiencies in product applications can be identified earlier, review times likely will fall and people will have access to new products more rapidly, FDA officials say. Nearly 5,000 new drugs, biologics, medical devices and animal drugs were approved in 2002. With fewer repeated reviews, called "cycles" by the FDA, there could have been even more.

Approvals that take more than one review to complete are not in the best interest of the public, the agency, or the company submitting the product application. From a public health standpoint, multiple-cycle reviews--when an application must be corrected and resubmitted a number of times before an FDA review can be completed--mean that safe and effective new products are not available to patients and health care providers in a timely manner. Multiple-cycle reviews prior to approval also can require substantial additional resources both for the FDA and the sponsor.

To help make innovative medical technologies available sooner, and to reduce the costs of developing safe and effective medical products, the FDA launched an initiative in January that offers guidance to companies it regulates so that they will have a better sense of what is expected on product applications. The initiative involves all four of the agency's medical product review centers (drugs, biologics, medical devices, and veterinary medicine) and focuses on:

* Reducing delays and costs in product approvals by avoiding multiple-review cycles

* Improving the review process through a quality systems approach to medical product review

* Expanding guidance documents to reduce uncertainty and increase efficiency for product development.

The agency has begun analyzing the root causes of product approvals that require more than one review cycle. With the reauthorization of the Prescription Drug User Fee Act (PDUFA), and the enactment of the similar Medical Device User Fee and Modernization Act (MDUFMA), the FDA expects to improve the quality and frequency of communications between the agency and drug, biologic, and medical device manufacturers. Both of these laws require fees paid by manufacturers to give the FDA the resources it needs to determine if a new drug, biologic or medical device should be approved.

In addition, the FDA will form working groups to oversee guidance development for priority areas such as treatments for cancer, diabetes and obesity.

Finding Solutions

Common problems with product applications significant enough to delay approval include unexpected safety issues or failure to demonstrate a drug or device's effectiveness. …

The rest of this article is only available to active members of Questia

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Buy instant access to cite pages or passages in MLA 8, MLA 7, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

(Einhorn 25)

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Note: primary sources have slightly different requirements for citation. Please see these guidelines for more information.

Cited article

FDA Begins Product Approval Initiative: In an Ideal World, All New Medical Products Proven to Be Safe and Effective Would Be Approved the First Time They Were Considered by the Food and Drug Administration. A Company Would Submit an Application with All the Required Information, and the Agency Would Perform a Timely Review and Then Approve the Product for Marketing
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Help
Full screen
Items saved from this article
  • Highlights & Notes
  • Citations
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

matching results for page

    Questia reader help

    How to highlight and cite specific passages

    1. Click or tap the first word you want to select.
    2. Click or tap the last word you want to select, and you’ll see everything in between get selected.
    3. You’ll then get a menu of options like creating a highlight or a citation from that passage of text.

    OK, got it!

    Cited passage

    Style
    Citations are available only to our active members.
    Buy instant access to cite pages or passages in MLA 8, MLA 7, APA and Chicago citation styles.

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

    1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

    Cited passage

    Thanks for trying Questia!

    Please continue trying out our research tools, but please note, full functionality is available only to our active members.

    Your work will be lost once you leave this Web page.

    Buy instant access to save your work.

    Already a member? Log in now.

    Search by... Author
    Show... All Results Primary Sources Peer-reviewed

    Oops!

    An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.